HK1166016A1 - The use of glucan on upper respiratory tract infection symptoms and psychological well being - Google Patents

The use of glucan on upper respiratory tract infection symptoms and psychological well being

Info

Publication number
HK1166016A1
HK1166016A1 HK12106829.0A HK12106829A HK1166016A1 HK 1166016 A1 HK1166016 A1 HK 1166016A1 HK 12106829 A HK12106829 A HK 12106829A HK 1166016 A1 HK1166016 A1 HK 1166016A1
Authority
HK
Hong Kong
Prior art keywords
glucan
respiratory tract
upper respiratory
tract infection
infection symptoms
Prior art date
Application number
HK12106829.0A
Other languages
English (en)
Chinese (zh)
Inventor
Donald J Cox
Steven Talbot
Original Assignee
Biopolymer Engineering Inc Dba Biothera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopolymer Engineering Inc Dba Biothera Inc filed Critical Biopolymer Engineering Inc Dba Biothera Inc
Publication of HK1166016A1 publication Critical patent/HK1166016A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
HK12106829.0A 2007-09-27 2012-07-11 The use of glucan on upper respiratory tract infection symptoms and psychological well being HK1166016A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97573407P 2007-09-27 2007-09-27

Publications (1)

Publication Number Publication Date
HK1166016A1 true HK1166016A1 (en) 2012-10-19

Family

ID=40511769

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106829.0A HK1166016A1 (en) 2007-09-27 2012-07-11 The use of glucan on upper respiratory tract infection symptoms and psychological well being

Country Status (15)

Country Link
US (1) US20110112048A1 (ko)
EP (2) EP2205250B1 (ko)
JP (2) JP2010540531A (ko)
KR (3) KR20100077175A (ko)
CN (3) CN102309503B (ko)
AU (1) AU2008305545B2 (ko)
CA (1) CA2700922C (ko)
CO (1) CO6321155A2 (ko)
ES (2) ES2675942T3 (ko)
HK (1) HK1166016A1 (ko)
MX (1) MX340664B (ko)
MY (1) MY156219A (ko)
PL (1) PL3072518T3 (ko)
TR (1) TR201807223T4 (ko)
WO (1) WO2009042230A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK500492010A3 (sk) * 2010-11-06 2012-06-04 Pleuran, S.R.O. Use of beta-D-glucane for decreasing undesirable effect of depression of immune response to excessive physical strain
CN103783370B (zh) * 2014-02-12 2015-05-20 北京同仁堂健康药业股份有限公司 一种保护呼吸道和肺部的组合物
CN115153023B (zh) * 2014-07-02 2024-06-04 嘉康利公司 用于增强免疫的组合物和方法
CN106038582A (zh) * 2016-05-06 2016-10-26 云南大学 以树突状细胞相关c型植物凝集素‑1为靶点的抗抑郁症药物及其筛选方法
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
PT3664894T (pt) 2017-08-11 2021-12-17 Biocodex Saccharomyces boulardii para o tratamento de perturbações do humor
MX2020004158A (es) 2017-10-23 2020-10-07 Nutrileads B V Polisacaridos pecticos enzimaticamente hidrolizados para tratar o prevenir infecciones.
CN111447935A (zh) 2017-12-04 2020-07-24 纽崔利兹有限公司 用于预防或治疗沙门氏菌病的组合物
US20220132902A1 (en) * 2020-08-12 2022-05-05 Pharmavite, Llc Prebiotic composition of pectin, beta-glucan, xylooligosaccharide and/or ashwagandha and a method of improving mood

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
CA2066172A1 (en) 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
WO1991003248A2 (en) * 1989-09-08 1991-03-21 Alpha Beta Technology, Inc. Method for immune system activation
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5811542A (en) 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5576015A (en) 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
US6130244A (en) * 1998-02-25 2000-10-10 Abbott Laboratories Product and method to reduce stress induced immune suppression
JP2002209598A (ja) * 2001-01-15 2002-07-30 Kirin Brewery Co Ltd 酵母由来可溶性多糖
US6939864B1 (en) * 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
KR20030087383A (ko) * 2002-05-08 2003-11-14 강상모 효모벽 추출물의 베타-글루칸을 이용한 건강증진 방법
DE202004013521U1 (de) * 2004-08-30 2006-01-05 Almapharm Christian F.A. Botzenhardt Gmbh + Co Präparat aus beta-Glucan und Nukleotid zur Verabreichung an Tiere
US20060084629A1 (en) * 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
JP2007190002A (ja) * 2006-01-16 2007-08-02 Elson Kk ストレス適応形成を促進させる機能性飲食品

Also Published As

Publication number Publication date
WO2009042230A1 (en) 2009-04-02
CN102309503B (zh) 2013-11-20
ES2675942T3 (es) 2018-07-13
MX340664B (es) 2016-07-20
KR20100077175A (ko) 2010-07-07
CA2700922C (en) 2016-07-05
JP6078105B2 (ja) 2017-02-08
EP3072518A1 (en) 2016-09-28
EP2205250A1 (en) 2010-07-14
EP2205250B1 (en) 2016-05-04
ES2580159T3 (es) 2016-08-19
AU2008305545A1 (en) 2009-04-02
AU2008305545B2 (en) 2014-07-17
CN105326852A (zh) 2016-02-17
CA2700922A1 (en) 2009-04-02
CN102309503A (zh) 2012-01-11
JP2010540531A (ja) 2010-12-24
EP3072518B1 (en) 2018-05-09
TR201807223T4 (tr) 2018-06-21
PL3072518T3 (pl) 2018-10-31
EP2205250A4 (en) 2011-04-06
MY156219A (en) 2016-01-29
CN105326852B (zh) 2018-11-23
MX2010003462A (es) 2010-08-18
JP2015155475A (ja) 2015-08-27
KR20150064233A (ko) 2015-06-10
KR20160067982A (ko) 2016-06-14
CO6321155A2 (es) 2011-09-20
US20110112048A1 (en) 2011-05-12
CN101873860A (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
HK1166016A1 (en) The use of glucan on upper respiratory tract infection symptoms and psychological well being
EP2205303A4 (en) MEDICAL INHALATION DEVICES AND COMPONENTS THEREOF
EP2049054A4 (en) NASAL AND ORAL PATIENT INTERFACE
IL249165A0 (en) Use of an antigen-mhc complex to prepare drugs for the prevention and treatment of autoimmune conditions
GB0721739D0 (en) medicinal inhalation devices and components thereof
GB0611131D0 (en) Nicotine inhalation therapies - smoking cessation and other medical uses
BRPI0820581A2 (pt) Dispositivo de interface com paciente, e, cânula nasal
EP2097012A4 (en) DEVICES AND METHOD FOR TREATING HEART FAILURE
IL182783A0 (en) Oral nasal cannula
EP2026723A4 (en) NOSE BREATHING APPARATUS
GB0817279D0 (en) A releasable mask and disposable body thereof
IL197240A0 (en) Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
EP2213328A4 (en) VALVE ELEMENT AND MEDICAL INSTRUMENT
EP2213327A4 (en) VALVE ELEMENT AND MEDICAL INSTRUMENT
HK1137807A1 (en) Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure
EP2164433A4 (en) ANCHORED RESPIRATORY TRACT IMPLANTS AND METHODS USING THE SAME
EP1879666A4 (en) PATIENT INTERFACE WITH AIRWAY GAS METER
GB0721737D0 (en) Medicinal inhalation devices and components thereof
LT2081650T (lt) Nosinis kvėpavimo filtras
EP2086646A4 (en) NOSE CATHETER WITH INTERNAL AND EXTERNAL AIR FLOWS
IL178815A0 (en) The treatment of respiratory disease
AU311197S (en) Respiratory mask elbow
PL2219658T3 (pl) Kompozycja oparta na bakteriach probiotycznych w połączeniu z prebiotykiem i jej zastosowanie w zapobieganiu i/lub leczeniu schorzeń oddechowych i/lub infekcji oraz do polepszenia funkcjonalności jelit
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL182407A0 (en) Use of agomelating in obtaining medicaments intended for the treatment of generalized anxiety disorder